Clinical trial NCT05066334: Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD
Official title: Intervertebral Disc Regeneration Mediated by Autologous Mesenchymal Stem/Stromal Cells Intradiscal Injection: a Phase IIB Randomized Clinical Trial - DREAM Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Intervertebral Disc Degeneration
Chronic Low-back Pain
Keywords: Low Back Pain
Spine
Intervertebral Disc Degeneration
Mesenchymal Stem Cells
Bone Marrow
Lead sponsor: Fondazione Policlinico Universitario Campus Bio-Medico
Sponsor class: OTHER
Collaborators: name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
name: Center for Outcomes Research and Clinical Epidemiology, Italy
First posted: 2021-10-04
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be randomized in 2 arms of 26 patients and followed up for 24 months.
Primary purpose: TREATMENT

Brief summary: DREAM is a phase II B efficacy monocentric, prospective, randomized, controlled double blinded trial, comparing intra-discal autologous adult bone marrow mesenchymal stem cells (BM-MSC) therapy and sham treated controls in subjects with chronic (\> 6 months) Low Back Pain (LBP) due to lumbar multilevel (max. 3 levels) intervertebral disc degeneration (IDD) unresponsive to conventional therapy.

Duration of the recruitment period has been estimated to be 12 months. The efficacy of intradiscal injection of autologous BM-MSC in reducing chronic LBP due to multilevel lumbar IDD will be evaluated after 24 months in terms of pain relief (VAS), functionality (ODI) and quality of life (SF36).

Detailed description: Low back pain (LBP) is the global leading cause of disability, and furthermore rates sixth in terms of overall disease burden, in both developed and developing countries. LPB is a condition of all ages, from children to elderly, affecting 60-70 percent of the global population during life, and \~700 million people each year. LBP prevalence increases with age, and with populations ageing worldwide, the societal and economic burden associated with LBP will increase substantially over coming years.

Current LBP therapies are aimed at pain reduction, and do not provide restorative treatment. Such conservative strategies (e.g. painkillers and musculoskeletal rearrangement by manual and physiotherapy) rarely address the actual cause of LBP.

In a healthy spine, intervertebral discs (IVDs) separate the vertebrae to provide complex spinal flexibility while supporting large spinal loads. Intervertebral disc degeneration (IDD) is widely recognized as a major contributor to LBP, responsible for at least 40 percent of LBP cases. A key characteristic of IVD degeneration is loss of matrix integrity, thereby causing biomechanical functional failure.

Today, no therapy can restore IVD function or provide long-term relief from symptomatic IDD. New treatment strategies concentrate on treating IDD at an early stage. Stem cell research offers exciting possibilities, and advanced cell-based therapies are considered highly promising strategies in treating IVD degeneration and LBP. Encouraging results suggest that cell-based, regenerative therapies may provide the world first effective therapy for this common and debilitating disease.

The objective of DREAM is to generate efficacy and tolerability profiles of a single injection of 15 million of cells/ml of autologous BM-MSC for each disc affected by IDD (up to 3 discs) versus sham procedure. The potential of BM-MSC to lead to a disease-modifying therapeutic option for the treatment of this chronic and debilitating disease will be assessed by Magnetic Resonance Imaging (MRI) after 6 months, 1 and 2 years.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent.
* Symptomatic chronic LBP due to moderate IDD (modified Pfirrmann score 3-4, Griffith score 3-7) at max.3 levels of the lumbar spine unresponsive to conservative treatment, physical and medical for at least 6 months. Physical treatment includes physiotherapy. Medical treatments includes nonsteroidal anti-inflammatory drugs (NSAID), paracetamol, opioids and myorelaxant.
* Annulus fibrosus intact, demonstrated by MRI.
* Pain baseline \> 40 mm on VAS (0- 100).
* NSAID washout of at least 2 days before screening.
* Painkillers washout of at least 24 hours before screening.
* For females of childbearing potential, a negative pregnancy test must be documented at Screening.
* Men and women should use effective contraception during treatment and for at least 24 months after BM-MSC discontinuation. As a precautionary measure, breast-feeding should be discontinued during treatment with BM-MSC and should not be restarted after discontinuation of BM-MSC.

Exclusion Criteria:

* Congenital or acquired diseases leading to spine deformations that may upset cell application (scoliosis, isthmus lesion, sacralization and hemisacralization, degenerative spondylolisthesis).
* Spinal segmental instability assessed by dynamic X-Ray.
* Symptomatic facet joints syndrome on MRI (facet joints hyperintensity and hypertrophy evaluated at coronal T2 weighted MRI).
* Prior to the screening visit, has received:
* Oral corticosteroid therapy within the previous 3 months, OR
* Intramuscular, intravenous or epidural corticosteroid therapy within the previous 3 months
* Presence of a 4th level with symptomatic IDD (modified Pfirrmann score 3-4, Griffith score 3-7) in the lumbar spine.
* Spinal canal stenosis (Schizas score \> B).
* History of spinal infection.
* Lumbar disc herniation and sciatica.
* Endplate abnormality such as Schmorl's Nodes.
* Previous discal puncture or previous spine surgery.
* IDD with Modic II and III changes on MRI images.
* Patients not eligible to the intravertebral disc surgery.
* Patients who have the risk to undergo a surgery in the next 6 months.
* Patients with local infusion device/devices for corticosteroids.
* Obesity with body mass index (BMI in Kg/size in m\^2) greater than 35 (obesity grade II).
* Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.
* Abnormal blood tests: hepatic (alanine amino transferase \[ALT\] and/or aspartate aminotransferase \[AST\] \> 1.5 × upper limit of normal \[ULN\]), renal, pancreatic or biliary disease, blood coagulation disorders, anemia or platelet count of \< 100 × 10\^9/L.
* Pregnant or lactating women, or premenopausal women not using an acceptable form of birth control, are ineligible for inclusion. Contraception will be maintained during treatment and until the end of relevant systemic exposure. Additional pregnancy testing will be performed at the end of relevant systemic exposure. The patients will be required to use contraception from initial treatment administration until 24 months after the last dose of study drug.
* In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is strongly recommended.
* Positive serology for following infection: Syphilis, HIV, Hepatitis B, or C.
* Contraindication to MRI assessed by the investigator.
* Intolerance or allergy to local anaesthesia.
* Any history of Cancer or immunodeficiency disease.
* Previous transplantation.

Primary outcomes:
measure: Pain Change
timeFrame: From Baseline to Month 24
measure: Functional disability index evaluation
timeFrame: From Baseline to Month 24
Secondary outcomes:
measure: Disability evolution
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Quality of life evolution
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Drug consumption of rescue painkillers medication
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Measurement of pain
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Employment and work status assessment
timeFrame: Baseline and 24 months
measure: Structural assessment
timeFrame: Baseline, 6, 12 and 24 months
measure: Evaluation of costs
timeFrame: 12 and 24 months
measure: Body Mass Index evaluation
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Haematological evaluation: safety parameter
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Coagulation status: safety parameter
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Metabolic functions: safety parameter
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Inflammation: safety parameter
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Urinalysis
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Spine examination
timeFrame: Baseline, 3, 6, 12 and 24 months
measure: Specific Adverse Events Evaluation
timeFrame: Baseline, 3, 6, 12 and 24 months
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Campus Bio-Medico University of Rome
Study officials:
affiliation: Campus Bio-Medico University of Rome
name: Gianluca Vadalà, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: